Antihyperlipidemic activity of Marchantia paleacea herb and Zingiber officinale var. Rubrum rhizome ethanol extracts in Triton X-100-induced mice
DOI:
https://doi.org/10.35814/jifi.v22i2.1458Keywords:
Antihyperlipidemic, CHOD PAP method, Marchantia paleacea, total cholesterol levels, Triton X-100 induced, Zingiber officinale var. RubrumAbstract
Non-communicable diseases cause 71% of deaths in the world, one of which is caused by dyslipidemia. Dyslipidemia has been established as a cause of various non-communicable diseases such as obesity and heart disease. This study aims to determine the antihyperlipidemic activity of the ethanol extract of the liverworts of Marchantia paleacea (EEMP) and the rhizome of Zingiber officinale var. rubrum (EEZOR) on male mice induced by Triton X-100. Grouping the number of test animals per group based on the Federer formula. Triton X-100 is used as an inducer of hyperlipidemic given intraperitoneally at a dose of 140 mg/kg body weight. Total cholesterol levels were measured by the colorimetric enzymatic method (CHOD-PAP) using a UV-Vis clinic photometer. Results from ethanol extract of the herb liverwort Marchantia paleacea (EEMP) and red ginger rhizomes Zingiber officinale var. Rubrum (EEZOR) can respectively reduce total hypercholesterol levels in male mice induced by Triton X-100 whose data were analyzed using the One-Way Anova test. The results of optimal dose of EEMP 200 mg/kg bw had the highest percentage of antihyperlipidemic activity and effectiveness (%) and also had a significant reduction in total cholesterol levels compared to the negative control group (p<0.05). While the results for the optimal dose of EEZOR 1000 mg/kg bw with the highest percentage of activity and effectiveness (%) and having a significant decrease compared to the negative control group (p <0.05). In conclusion, these findings suggest that both extracts have potential as natural antihyperlipidemic agents that can be further explored in the management of hyperlipidemic (dyslipidemic) and related non-communicable diseases.
References
Downloads
Published
Issue
Section
License
Licencing
All articles in Jurnal Ilmu Kefarmasian Indonesia are an open-access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which permits unrestricted non-commercial used, distribution and reproduction in any medium.
This licence applies to Author(s) and Public Reader means that the users mays :
- SHARE:
copy and redistribute the article in any medium or format - ADAPT:
remix, transform, and build upon the article (eg.: to produce a new research work and, possibly, a new publication) - ALIKE:
If you remix, transform, or build upon the article, you must distribute your contributions under the same license as the original. - NO ADDITIONAL RESTRICTIONS:
You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
It does however mean that when you use it you must:
- ATTRIBUTION: You must give appropriate credit to both the Author(s) and the journal, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
You may not:
- NONCOMMERCIAL: You may not use the article for commercial purposes.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

















